MX2007003910A - T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents. - Google Patents

T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.

Info

Publication number
MX2007003910A
MX2007003910A MX2007003910A MX2007003910A MX2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A MX 2007003910 A MX2007003910 A MX 2007003910A
Authority
MX
Mexico
Prior art keywords
tcr
cell receptors
terminus
amino acid
acid sequence
Prior art date
Application number
MX2007003910A
Other languages
Spanish (es)
Inventor
Bent Karsten Jakobsen
Torben Bent Andersen
Original Assignee
Avidex Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0421836.8A external-priority patent/GB0421836D0/en
Priority claimed from GB0427584A external-priority patent/GB0427584D0/en
Application filed by Avidex Ltd filed Critical Avidex Ltd
Publication of MX2007003910A publication Critical patent/MX2007003910A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)

Abstract

The present invention provides a dimeric TCR (dTCR) or single-chain TCR (scTCR) associated with selected therapeutic agents, wherein said TCR comprises a first segment constituted by an amino acid sequence corresponding to a TCR chain variable domain sequence fused to the N terminus of an amino acid sequence corresponding to a TCR chain constant domain extracellular sequence, a second segment constituted by an amino acid sequence corresponding to a TCR a chain variable domain fused to the N terminus of an amino acid sequence corresponding to TCR a chain constant domain extracellular sequence, a disulfide bond between the first and second chains, said disulfide bond being one which has no equivalent in native a T cell receptors, and in the case of said scTCRs further comprising a linker sequence linking the C terminus of the first segment to the N terminus of the second segment, or vice versa, the length of the linker sequence and the position of the disulfide bond being suc h that the variable domain sequences of the first and second segments are mutually orientated substantially as in native a T cell receptors.
MX2007003910A 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents. MX2007003910A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0421836.8A GB0421836D0 (en) 2004-10-01 2004-10-01 T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents
US62106304P 2004-10-25 2004-10-25
GB0427584A GB0427584D0 (en) 2004-12-16 2004-12-16 T cell receptors containing a novel disulfide interchain bond linked to immunomodulatory agents
PCT/GB2005/003752 WO2006037960A2 (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents

Publications (1)

Publication Number Publication Date
MX2007003910A true MX2007003910A (en) 2007-06-07

Family

ID=36000822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003910A MX2007003910A (en) 2004-10-01 2005-09-29 T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.

Country Status (6)

Country Link
EP (1) EP1809669A2 (en)
JP (1) JP2008514685A (en)
AU (1) AU2005291039A1 (en)
CA (1) CA2582963A1 (en)
MX (1) MX2007003910A (en)
WO (1) WO2006037960A2 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1772465E (en) 2005-01-05 2009-05-21 F Star Biotech Forsch & Entw Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503861B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING T-CELL RECEPTORS
CN101802006B (en) 2007-06-26 2013-08-14 F-星生物技术研究与开发有限公司 Display of binding agents
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CN102161998B (en) 2011-01-14 2013-01-09 中国人民解放军军事医学科学院附属医院 Deoxyribonucleic acid (DNA) vaccine based on B7-1-PE40KDEL exotoxin fusion gene and application thereof
BR112013031262A2 (en) 2011-06-09 2016-11-22 Us Health "exotoxins a from pseudomonas with less immunogenic bet cell epitopes, and their use in cancer treatment and prevention, as well as chimeric molecule, nucleic acid, expression vector, cells, pharmaceutical composition and methods to inhibit target cell growth and endotoxin production and pseudomonas and chimeric molecule ".
US9206240B2 (en) 2011-09-16 2015-12-08 The United States of America, as represented by the Secretary, Department of Helath and Human Services Pseudomonas exotoxin A with less immunogenic B cell epitopes
JP2014530009A (en) * 2011-09-29 2014-11-17 エーピーオー‐ティー ビー．ヴイ． Multispecific binding molecules targeting abnormal cells
CN103130894B (en) * 2011-11-30 2017-04-12 中国医学科学院基础医学研究所 Recombinant single-chain antibody G5-4ScFv of anti-human gamma delta T cell receptor (TCR) monoclonal antibody and encoding gene and application thereof
CA2860914A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
MX2016000231A (en) * 2013-06-26 2016-10-05 Guangzhou Xiangxue Pharmaceutical Co Ltd High-stability t-cell receptor and preparation method and application thereof.
CA2967073A1 (en) * 2014-11-07 2016-05-12 Guangzhou Xiangxue Pharmaceutical Co. Ltd Soluble heterodimeric t cell receptor, and preparation method and use thereof
CN106279404A (en) * 2015-05-20 2017-01-04 广州市香雪制药股份有限公司 A kind of solvable and stable heterogeneous dimerization TCR
IL262772B2 (en) 2016-05-06 2023-10-01 Juno Therapeutics Inc Genetically engineered cells and methods of making the same
EP3464380A1 (en) 2016-06-02 2019-04-10 Immunocore Limited Dosing regimen for gp100-specific tcr - anti-cd3 scfv fusion protein
MA45491A (en) 2016-06-27 2019-05-01 Juno Therapeutics Inc CMH-E RESTRICTED EPITOPES, BINDING MOLECULES AND RELATED METHODS AND USES
CN110291402B (en) 2016-06-27 2023-09-01 朱诺治疗学股份有限公司 Method for identifying peptide epitopes, molecules binding such epitopes and related uses
CN110139873A (en) 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 HPV specific binding molecules
EP3548055A4 (en) * 2016-12-02 2020-08-19 University of Southern California Synthetic immune receptors and methods of use thereof
WO2018148445A1 (en) 2017-02-08 2018-08-16 Adimab, Llc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
KR20240060739A (en) 2017-02-20 2024-05-08 드래곤플라이 쎄라퓨틱스, 인크. Proteins binding her2, nkg2d and cd16
WO2019070541A1 (en) 2017-10-03 2019-04-11 Juno Therapeutics, Inc. Hpv-specific binding molecules
CA3081456A1 (en) 2017-11-01 2019-05-09 Editas Medicine, Inc. Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
JP2021502077A (en) 2017-11-06 2021-01-28 エディタス・メディシン，インコーポレイテッド Methods, compositions and components for CRISPR-CAS9 editing of CBLB on T cells for immunotherapy
CA3237846A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
JP2021520211A (en) 2018-04-05 2021-08-19 ジュノー セラピューティクス インコーポレイテッド T cells expressing recombinant receptors, related polynucleotides, and methods
CA3094468A1 (en) 2018-04-05 2019-10-10 Juno Therapeutics, Inc. Methods of producing cells expressing a recombinant receptor and related compositions
MX2020010460A (en) 2018-04-05 2021-01-29 Juno Therapeutics Inc T cell receptors and engineered cells expressing same.
EA202091977A1 (en) * 2018-05-28 2021-02-09 Драгонфлай Терапьютикс, Инк. MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D AND CD16 AND METHODS OF APPLICATION
BR112021002390A2 (en) 2018-08-09 2021-05-11 Juno Therapeutics Inc processes to generate modified cells and their compositions
EP3850366A1 (en) 2018-09-11 2021-07-21 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
KR20220016475A (en) 2019-05-01 2022-02-09 주노 쎄러퓨티크스 인코퍼레이티드 Cells, Associated Polynucleotides and Methods Expressing Recombinant Receptors at the Modified TFTFR2 Locus
US20210322471A1 (en) 2020-03-27 2021-10-21 Dcprime B.V. In vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
JP2023531531A (en) 2020-06-26 2023-07-24 ジュノ セラピューティクス ゲーエムベーハー Engineered T Cells Conditionally Expressing Recombinant Receptors, Related Polynucleotides, and Methods
WO2022060904A1 (en) 2020-09-16 2022-03-24 Obsidian Therapeutics, Inc. Compositions and methods for expression of t-cell receptors with small molecule-regulated cd40l in t cells
EP4240405A1 (en) 2020-11-05 2023-09-13 Mendus B.V. Use of tumor-independent antigens in immunotherapies
WO2023081900A1 (en) 2021-11-08 2023-05-11 Juno Therapeutics, Inc. Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
CN116496408A (en) * 2022-01-21 2023-07-28 广东菲鹏制药股份有限公司 Interleukin 21 and receptor complexes thereof
WO2023196884A1 (en) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Detection assay for human papillomavirus (hpv) type 16 (hpv-16)
US20240002800A1 (en) 2022-05-16 2024-01-04 Mendus B.V. Use of leukemia-derived cells for enhancing natural killer (nk) cell therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL208712B1 (en) * 2001-08-31 2011-05-31 Avidex Ltd Soluble t cell receptor
AU2003271904B2 (en) * 2002-10-09 2009-03-05 Adaptimmune Limited Single chain recombinant T cell receptors
NZ539226A (en) * 2002-11-09 2008-09-26 Medigene Ltd T cell receptor display
JP2006523437A (en) * 2002-12-03 2006-10-19 アヴィデックス リミテッド Receptor complex
GB0304068D0 (en) * 2003-02-22 2003-03-26 Avidex Ltd Substances

Also Published As

Publication number Publication date
CA2582963A1 (en) 2006-04-13
EP1809669A2 (en) 2007-07-25
AU2005291039A1 (en) 2006-04-13
WO2006037960A3 (en) 2006-08-03
JP2008514685A (en) 2008-05-08
WO2006037960A2 (en) 2006-04-13

Similar Documents

Publication Publication Date Title
MX2007003910A (en) T-cell receptors containing a non-native disulfide interchain bond linked to therapeutic agents.
JP2006502741A5 (en)
NZ764889A (en) Composition for treating diabetes mellitus comprising insulin and a glp-1/glucagon dual agonist
HRP20220865T1 (en) T cell receptors
GT200700059A (en) EXENDINE FUSION PROTEINS
MX2012003939A (en) Drug fusions and conjugates with extended half life.
HRP20170086T1 (en) Bifunctional polypeptides
PE20120514A1 (en) FUSIONS AND CONJUGATES OF INSULINOTROPIC AGENTS OR DRUGS INCRETINE WITH DAB ANTI-SERIAL ALBUMIN ANTIBODIES
AR081042A1 (en) PEPTIDES OF THE GLUCAGON SUPERFAMILY PRESENTING ACTIVITY OF THE RECEPTOR COUPLED TO PROTEINS G
UY31123A1 (en) NATURAL FUSION PROTEINS
CY1118243T1 (en) NEW TRANSPORT CONTAINERS AND LOAD TRANSPORT CONTAINER PARTS
GB201009493D0 (en) Modified recombinant factor viii and von willebrand factor and methods of use
AR075504A1 (en) MOLECULES OF ANTIBODIES THAT HAVE SPECIFICITY FOR THE HUMAN OX40
IN2015DN02913A (en)
PE20140260A1 (en) ANTIDIABETIC COMPOUNDS
PE20171325A1 (en) POLYPEPTIDES OF THE VARIANT ACTIVIN RECEPTOR AND USE OF THEM
WO2011101681A3 (en) Disulphide bond-stabilized functional soluble mhc class ii heterodimers
PE20141045A1 (en) BCMA BINDING PROTEINS (CD269 / TNFRSF17)
PL1761553T3 (en) Tumor-associated peptides that bind to mhc-molecules
WO2014052451A3 (en) Insulin analog dimers
PE20161153A1 (en) LONG-ACTING INSULIN AND USE OF THE SAME
DK2231860T3 (en) Polypeptide derived protein A and capable of binding PDGF
RS54359B1 (en) Anti cd37 antibodies
NO20071592L (en) GLP-1 and exendin-related invention
ATE388964T1 (en) MODIFIED SOLUBLE T-CELL RECEPTOR

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: ALSTOM RENEWABLE TECHNOLOGIES

FA Abandonment or withdrawal